drugset / Trial / NCT07656012
Re-evaluating the Duration in Children of TB Treatment
Phase 2
Not yet recruiting
230 enrolled
University of Wisconsin, Madison
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Current tuberculosis (TB) treatment is effective (works well), but it takes a long time to cure TB. This study will evaluate if TB treatment with a higher dose of rifampicin, one of the TB medicines, and shorter TB treatment duration is as effective and safe as the standard, TB treatment (with the usual rifampicin dose and usual duration). This study hopes to find a better shorter treatment that works as well as the current treatment (standard of care). This could benefit children worldwide who are getting TB treatment. Children 3 months to less than 10 years of age who have drug-susceptible TB (can be successfully treated with standard TB medicines) are eligible for this study.
Timeline
- Start
- 2026-10
- Primary completion
- 2030-09
- Completion
- 2030-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rifampicin | Small molecule | — | — |
| Background | Ethambutol | Small molecule | — | — |
| Background | Isoniazid | Small molecule | — | — |
| Background | Pyrazinamide | Small molecule | — | — |